{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subcutaneous+administration+of+recombinant+human+IGF-1",
    "query": {
      "intervention": "Subcutaneous administration of recombinant human IGF-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T17:27:44.186Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00915954",
      "title": "Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acromegaly",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Subcutaneous administration of recombinant human IGF-1",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Placebo",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2008-12",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-07-09",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00915954"
    },
    {
      "nct_id": "NCT04003207",
      "title": "Growth Hormone Treatment in Children With Phelan McDermid Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phelan McDermid Syndrome"
      ],
      "interventions": [
        {
          "name": "Recombinant human Growth hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swathi Sethuram",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-13",
      "completion_date": "2020-06-05",
      "has_results": true,
      "last_update_posted_date": "2024-05-02",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003207"
    },
    {
      "nct_id": "NCT00577577",
      "title": "Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [
        {
          "name": "rhIGF-I/rhIGFBP-3",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 69,
      "start_date": "2007-12",
      "completion_date": "2008-12-29",
      "has_results": true,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 12,
      "location_summary": "Orange, California • Sacramento, California • Kansas City, Kansas + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577577"
    },
    {
      "nct_id": "NCT00125190",
      "title": "Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Insulin-Like Growth Factor-1 Deficiency",
        "Growth Disorders"
      ],
      "interventions": [
        {
          "name": "rhIGF-1 (mecasermin) for a period of 86 weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2005-07",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125190"
    },
    {
      "nct_id": "NCT01777542",
      "title": "Treatment of Rett Syndrome With Recombinant Human IGF-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "Recombinant Human Insulin Growth Factor 1 (rhIGF-1)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "10 Years",
        "sex": "FEMALE",
        "summary": "2 Years to 10 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2013-01",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2018-03-26",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777542"
    },
    {
      "nct_id": "NCT00516386",
      "title": "Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anorexia Nervosa"
      ],
      "interventions": [
        {
          "name": "RhIGF-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 18 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2007-03",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-18",
      "last_synced_at": "2026-09-29T17:27:44.186Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516386"
    }
  ]
}